Cyclerion Therapeutics, Inc.

About Cyclerion Therapeutics, Inc.

Cyclerion is a biopharmaceutical company focused on advancing personalized therapeutic approaches for treatment-resistant depression (TRD). Their strategy integrates therapies with validated modes of action and a tech-enabled, personalized delivery system to transform mental health care and offer hope to patients who have not responded to traditional treatments.

Products & Services

Personalized TRD Treatment:A pioneering therapeutic approach for treatment-resistant depression (TRD) that combines generic anesthetics with a personalized biofeedback-driven device to reset dysregulated brainwave patterns, maximizing safety and efficacy.

Specialties

Personalized Medicine Treatment-Resistant Depression (TRD) Neuropsychiatric Therapies Tech-Enabled Delivery Systems

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Investment T: - FT: Equity Investment	A: 5000000 MR: - FA: $5M FAN: 5000000	D: 2023-04-03 FD: 2023-04-03	1 investors

Equity Investment Latest

2023-04-03

$5.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Regina Graul

President and CEO, Cyclerion

R

Rhonda Chicko

Chief Financial Officer

E

Errol De Souza

Chairman of the Board of Directors

P

Peter Hecht

Member of the Board of Directors

M

Michael J. Higgins

Member of the Board of Directors

S

Steven Hyman

Distinguished Service Professor and Harald McPike Professor of Stem Cell and Regenerative Biology

View 13 more team members with Pro

Unlock Full Team Directory

Recent News